DelveInsight Releases Report on Postherpetic Neuralgia Drug Pipeline
DelveInsight has released a comprehensive report analyzing the current state and future outlook of drug development for postherpetic neuralgia (PHN) through 2026.
DelveInsight Releases Report on Postherpetic Neuralgia Drug Pipeline
Market research firm DelveInsight has published a report providing an in-depth analysis of the postherpetic neuralgia (PHN) drug development landscape through 2026. The "Postherpetic Neuralgia - Pipeline Insight, 2026" report covers over six companies and more than six pipeline drugs currently in various stages of clinical development.
PHN is a common and painful complication that can occur after a shingles outbreak, caused by the reactivation of the varicella-zoster virus (VZV). The condition is characterized by persistent, burning, or lancinating pain along a specific dermatomal pattern that lasts for months after the rash has healed. The elderly and immunocompromised individuals are particularly at risk.
The report assesses PHN drug candidates based on product type, development stage, route of administration, and molecule type. It includes detailed profiles for both clinical and non-clinical products, as well as identifies inactive pipeline products.
According to DelveInsight, treatment for PHN often requires a multimodal approach, including anticonvulsants, antidepressants, topical agents, and nerve blocks. Emerging drug candidates aim to offer more effective and less side-effect-prone treatments for pain relief and improving patients' quality of life.